Exagen (FRA:E08A) Short-Term Debt : €0.25 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Exagen Short-Term Debt?

Exagen's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.25 Mil.

Exagen's quarterly Short-Term Debt declined from Sep. 2023 (€0.25 Mil) to Dec. 2023 (€0.24 Mil) but then increased from Dec. 2023 (€0.24 Mil) to Mar. 2024 (€0.25 Mil).

Exagen's annual Short-Term Debt increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.18 Mil) and increased from Dec. 2022 (€0.18 Mil) to Dec. 2023 (€0.24 Mil).

Exagen Short-Term Debt Historical Data

The historical data trend for Exagen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Short-Term Debt Chart

Exagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

0.18

0.24

Exagen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															0.24	0.24	0.25	0.24	0.25

Exagen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Exagen Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Exagen's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Exagen (FRA:E08A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (FRA:E08A) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

XGN:USA

Address

1261 Liberty Way, Vista, CA, USA, 92081

Website

https://www.exagen.com

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Exagen (FRA:E08A) Headlines

No Headlines